Back to Blog
2025.02.12
Lantern Festival: Let's Celebrate the Festival of Lanterns Together!

Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.
Related articles
The Health 'Shadow War' Around Menopause: This Test Helps You Clear 'Landmines' Early — Endometrial Cancer Edition
2025.07.15
CISPOLY's Methylation Tests for Three Gynecologic Cancers Included in the Group Standard of Technical Specification for Tumor DNA Methylation Biomarker Detection
2026.07.14
New Publication | Non-Invasive Testing Aids Early Endometrial Cancer Diagnosis: Cervical CDO1/CELF4 Methylation Test Prospectively Validated
2026.06.02
